Prostate cancer and the gay male

Journal of Gay and Lesbian Psychotherapy

Volumn 9, Issue 1-2, 2005, Pages 9-27

  Santillo, Vincent M ^a   Lowe, Franklin C ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c New York Presbyterian Columbia University Medical Center   (United States)

Author keywords

AIDS; Anabolic steroids; Anal sex; Cancer; Diet; Erectile dysfunction; Finasteride; Gay; Gay couples; Gay relationships; HIV; Homosexuality; Impotence; Incontinence; Informed consent; Prostate; Prostatectomy; Psa testing; Testosterone

Indexed keywords

EID: 84993678626     PISSN: 08917140     EISSN: 15407128     Source Type: Journal    
DOI: 10.1300/J236v09n01_02     Document Type: Article

References (44)

1. American Cancer Society. 2004. Cancer Facts & Figures 2004.
2. Andriole, G., Guess, H., Epstein, J., Wise, H., Kadmon, D., Crawford, E., Hudson, P., Jackson, C., Romas, N., Patterson, L., Cook, T., and Waldstreicher, J., 1998. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer:results of a randomized, double-blind, placebo-controlled clinical trial. Urology, 52:195–202.
3. Baquet, C., Horm, J., Gibbs, T., and Greenwald, P., 1991. Socioeconomic factors and cancer incidence among blacks and whites. J. Natl. Cancer Inst., 83:551–557.
4. Bolding, G., Sherr, L., Maguire, M., and Elford, J., 1999. HIV risk behaviours among gay men who use anabolic steroids. Addiction, 94:1829–1835.
5. Bolding, G., Sherr, L., and Elford, J., 2002. Use of anabolic steroids and associated health risks among gay men attending London gyms. Addiction, 97:195–203.
6. Carter, H., Partin, A., Walsh, P., Retik, A., and Vaughn, E., 2002. “Diagnosis and staging of prostate cancer”. In Campbell 's Urology,., 8th ed., 3055–3079. Philadelphia, PA:WB Saunders.
7. Catalona, W., Ramos, C., Carvalhal, G., and Yan, Y., 2000. Lowering PSA cutoffs to enhance detection of curable prostate cancer. Urology, 55:791–795.
8. Centers for Disease Control and Prevention. 2003. Prostate Cancer:The Public Health Perspective, Washington, DC:Author.
9. Cooksley, C., Hwang, L., Waller, D., and Ford, C., 1999. HIV-related malignancies:Community-based study using linkage of cancer registry and HIV registry data. International J. STD&AIDS, 10:795–802.
10. Crum, N., Hale, B., Utz, G., and Wallace, M., 2002. Increased risk of prostate cancer in HIV infection?. AIDS, 16:1703–1704.
11. D'Amico, A., Crook, J., Beard, C., DeWeese, T., Hurwitz, M., and Kaplan, I., 2002. “Radiation therapy for prostate cancer.”. In Campbell's Urology, 8th ed., Edited by:Walsh, P., Retik, A., and Vaughn, E., 3147–3170. Philadelphia, PA:WB Saunders.
12. Dean, L., Meyer, I., Robinson, K., Sell, R., Sember, R., Silenzio, V., Bowen, D., Bradford, J., Rothblum, E., Scout White, J., Dunn, P., Lawrence, A., Wolfe, D., and Xavier, J., 2000. Lesbian, gay, bisexual, and transgender health:Findings and Concerns. J. Gay & Lesbian Medical Association, 4:101–151.
13. Eastham, J., Scardino, P., Walsh, P., Retik, A., and Vaughn, E., 2002. “Radical Prostatectomy.”. In Campbell's Urology., 8th ed., 3080–3106. Philadelphia, PA:WB Saunders.
14. Epstein, J., Walsh, P., Retik, A., and Vaughn, E., 2002. “Pathology of prostatic neoplasia”. In Campbell's Urology, 8th ed., Vol. 86, 3025–3037. Philadelphia, PA:WB Saunders.
15. Gann, P., Hennekens, C., Sacks, F., Grodstein, F., Giovannucci, E., and Stempfer, M., 1994. Prospective study of plasma fatty acids and risk of prostate cancer. J. Natl. Cancer Inst., 86:281–286.
16. Goetzl, D., 2000. Propecia aims $2 mil push at gay men. Advertising Age, 71(12):8
17. Goldstone, S. E., 2005. The ups and downs of gay sex after prostate cancer treatment. J. Gay & Lesbian Psychotherapy, 9(1/2):43–55.
18. Hanks, G., 2000. The case for external beam treatment of early-stage prostate cancer. Urology, 55:301–305.
19. Heyman, E., and Rosner, T., 1996. Prostate cancer:An intimate view from patients and wives. Urol. Nurs., 16:37–44.
20. Jackson, L., 2005. Surviving yet another challenge. J. Gay & Lesbian Psychotherapy, 9(1/2):101–107.
21. Jemal, A., Thomas, A., Murray, T., and Thun, M., 2002. Cancer statistics. CA Cancer J. Clin., 52:23–47.
22. Kaminski, J., Summers, J., Ward, M., Huber, M., and Minev, B., 2003. Immunotherapy and prostate cancer. Cancer Treatment Reviews, 29:199–209.
23. Kirby, R., 1998. Treatment options for early prostate cancer. Urology, 52:948–962.
24. Klein, L., and Lowe, F., 1997. The effects of prostatic manipulation on prostate-specific antigen levels. Urol. Clin. N. America, 24:293–297.
25. Kwan, D., and Lowe, F., 1995. Genitourinary manifestations of the acquired immunodeficiency syndrome. Urology, 45:13–27.
26. Levinson, A., Nagler, E., and Lowe, F., 2005. The approach to management of localized prostate cancer in patients with Immunodeficiency Syndrome. Urology, 65 press
27. Litwin, M., Flanders, S., Pasta, D., Stoddard, M., Lubeck, D., and Henning, J., 1999. Sexual function and bother after radical prostatectomy or radiation for prostate cancer:Multivariate quality-of-life analysis from CaPSURE. Urology, 54:503–508.
28. Lowe, F., Cavallo, C., and Kahane, H., 2003. Epidemiological evidence suggesting a PSA cut-point of 2.5 ng/mL for initiating a prostate biopsy:A review of 36, 316 patients with biopsy and PSA data. J. Urol., 169 Abstract DP 12, 341
29. Merck & Co., Inc. 1997. Propecia (Finasteride) full prescribing information White-house Station, NJ
30. Öubek, C., Lai, S., Sadek, S., Civantos, F., and Soloway, M., 1999. Age as a prognostic factor for disease recurrence after radical prostatectomy. Urology, 54:533–538.
31. Pienta, K., and Esper, P., 1993. Risk factors for prostate cancer. Ann. Intern. Med., 118:793–803.
32. Pound, C., Partin, A., Eisenberger, M., Chan, D., Pearson, J., and Walsh, P., 1999. Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281:1591–1597.
33. Reiter, R., deKernion, J., Walsh, P., Retik, A., and Vaughn, E., 2002. “Epidemiology, etiology, and prevention of prostate cancer”. In Campbell's Urology, 8th ed., Vol. 85, 3003–3024. Philadelphia, PA:WB Saunders.
34. Roberts, S., Blute, M., Bergstralh, E., Slezak, J., and Zincke, H., 2001. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin. Proc., 76:576–581.
35. Santos, J., Palacios, R., Ruiz, J., González, M., and Márquez, M., 2002. Unusual malignant tumours in patients with HIV infection. International J. STD & AIDS, 13:674–676.
36. SchrÖder, F., 2002. “Hormonal therapy of prostate cancer”. In Campbell's Urology, 8th ed., Edited by:Walsh, P., Retik, A., and Vaughn, E., Vol. 94, 3182–3208. Philadelphia, PA:WB Saunders.
37. Shinohara, K., Carroll, P., Walsh, P., Retik, A., and Vaughn, E., 2002. “Cryotherapy for prostate cancer.”. In Campbell's Urology., 8th ed., 3171–3181. Philadelphia, PA:WB Saunders.
38. Srirangam, S., Pearson, E., Grose, C., Brown, S., Collins, G., and O'Reilly, P., 2003. Partner's influence on patient preference for treatment in early prostate cancer. BJU Int., 92:365–369.
39. Steinberg, G., Carter, B., Beaty, T., Childs, B., and Walsh, P., 1990. Family history and the risk of prostate cancer. The Prostate, 17:337–347.
40. Terris, M., 2002. “Ultrasonography and biopsy of the prostate”. In Campbell's Urology, 8th ed., Edited by:Walsh, P., Retik, A., and Vaughn, E., 3038–3054. Philadelphia, PA:WB Saunders.
41. Thompson, I., Goodman, P., Tangen, C., Lucia, M., Miller, G., Ford, L., Lieber, M., Cespedes, R., Atkins, J., Lippman, S., Carlin, S., Ryan, A., Szczepanek, C., Crowley, J., and Coltman, C., 2003. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med., 349:215–24.
42. Walsh, P., and Worthington, J., 2001. Dr. Patrick Walsh's Guide to Surviving Prostate Cancer., New York, NY:Warner Books.
43. Yeland, C., and Tiggemann, M., 2003. Muscularity and the gay ideal:Body dissatisfaction and disordered eating in homosexual men. Eating Behaviors, 4:107–116.
44. Zeegers, M., Jellema, A., and Ostrer, H., 2003. Empiric risk of prostate carcinoma for relatives of patients with prostate carcinoma. Cancer, 97:1894–1903.